NRX Pharmaceuticals, Inc. Debt Conversion, Converted Instrument, Amount
NRX Pharmaceuticals, Inc. (NRXP) reported Debt Conversion, Converted Instrument, Amount of $100.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2022-03-31
- NRX Pharmaceuticals, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $100.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2020-12-31 | $100.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |